drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB05679 | DB08908 | 1,683 | 713 | [
"DDInter1907",
"DDInter564"
] | Ustekinumab | Dimethyl fumarate | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
1683,
24,
713
]
],
[
[
1683,
63,
1083
],
[
1083,
24,
713
]
],
[
[
1683,
24,
594
],
[
594,
24,
713
]
],
[
[
1683,
25,
725
],
[
725,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Bosutini... |
DB00439 | DB00673 | 289 | 723 | [
"DDInter341",
"DDInter112"
] | Cerivastatin | Aprepitant | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
289,
24,
723
]
],
[
[
289,
24,
466
],
[
466,
62,
723
]
],
[
[
289,
24,
214
],
[
214,
63,
723
]
],
[
[
289,
64,
600
],
[
600,
24,... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib an... |
DB11166 | DB11793 | 18 | 738 | [
"DDInter104",
"DDInter1297"
] | Antithrombin Alfa | Niraparib | Antithrombin Alfa is a recombinant antithrombin, an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
18,
24,
738
]
],
[
[
18,
63,
848
],
[
848,
24,
738
]
],
[
[
18,
64,
1564
],
[
1564,
24,
738
]
],
[
[
18,
25,
405
],
[
405,
24,
... | [
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
... | Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Antithrombin Alfa may lead to a major life threatening interaction when taken with Defibrotide and Defibroti... |
DB00652 | DB00986 | 234 | 1,192 | [
"DDInter1421",
"DDInter834"
] | Pentazocine | Glycopyrronium | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
234,
24,
1192
]
],
[
[
234,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
234,
24,
262
],
[
262,
24,
1192
]
],
[
[
234,
21,
28817
],
[
28817,
... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and... |
DB00554 | DB00863 | 1,027 | 1,194 | [
"DDInter1478",
"DDInter1568"
] | Piroxicam | Ranitidine | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
1027,
23,
1194
]
],
[
[
1027,
23,
1127
],
[
1127,
1,
1194
]
],
[
[
1027,
6,
16560
],
[
16560,
45,
1194
]
],
[
[
1027,
25,
1468
],
[
14... | [
[
[
"Piroxicam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Piroxicam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nizatidine"
],
[
"N... | Piroxicam may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound)
Piroxicam (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Ranitidine (Compound)
Piroxicam may lead to a major life threatening interaction when take... |
DB00731 | DB01175 | 1,144 | 318 | [
"DDInter1269",
"DDInter672"
] | Nateglinide | Escitalopram | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1144,
24,
318
]
],
[
[
1144,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1144,
21,
28850
],
[
28850,... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Nateglinide (Compound) causes Back pain (Side Effect) and Ba... |
DB06209 | DB08896 | 256 | 292 | [
"DDInter1508",
"DDInter1576"
] | Prasugrel | Regorafenib | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
256,
25,
292
]
],
[
[
256,
6,
6017
],
[
6017,
45,
292
]
],
[
[
256,
21,
29122
],
[
29122,
60,
292
]
],
[
[
256,
24,
643
],
[
643,
... | [
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Prasugrel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Regorafe... | Prasugrel (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Prasugrel (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Regorafenib (Compound)
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00013 | DB00465 | 1,255 | 886 | [
"DDInter1905",
"DDInter1010"
] | Urokinase | Ketorolac | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Moderate | 1 | [
[
[
1255,
24,
886
]
],
[
[
1255,
24,
24
],
[
24,
40,
886
]
],
[
[
1255,
64,
1578
],
[
1578,
24,
886
]
],
[
[
1255,
25,
1564
],
[
1564,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
"... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) resembles Ketorolac (Compound)
Urokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases whe... |
DB00445 | DB00477 | 322 | 216 | [
"DDInter655",
"DDInter363"
] | Epirubicin | Chlorpromazine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
322,
24,
216
]
],
[
[
322,
24,
1178
],
[
1178,
1,
216
]
],
[
[
322,
25,
684
],
[
684,
40,
216
]
],
[
[
322,
24,
1237
],
[
1237,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Epirubicin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpromazine (Com... |
DB00420 | DB00668 | 508 | 874 | [
"DDInter1532",
"DDInter652"
] | Promazine | Epinephrine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Moderate | 1 | [
[
[
508,
24,
874
]
],
[
[
508,
24,
688
],
[
688,
63,
874
]
],
[
[
508,
6,
7950
],
[
7950,
45,
874
]
],
[
[
508,
7,
3163
],
[
3163,
4... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Promazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Epinephrine (Compound)
Promazine (Compoun... |
DB00960 | DB08865 | 887 | 1,593 | [
"DDInter1471",
"DDInter448"
] | Pindolol | Crizotinib | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
887,
24,
1593
]
],
[
[
887,
18,
2602
],
[
2602,
45,
1593
]
],
[
[
887,
18,
4154
],
[
4154,
46,
1593
]
],
[
[
887,
18,
3616
],
[
3616,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Pindolol",
"{u} (Compound) downregulates {v} (Gene)",
"PTK2B"
],
[
"PTK2B",
"{u} (Gene) is bound by {v} (Compound)... | Pindolol (Compound) downregulates PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Pindolol (Compound) downregulates PPOX (Gene) and PPOX (Gene) is upregulated by Crizotinib (Compound)
Pindolol (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Crizotinib (Compound)
Pindolol (Comp... |
DB00938 | DB06764 | 455 | 1,090 | [
"DDInter1635",
"DDInter1788"
] | Salmeterol | Tetryzoline (ophthalmic) | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
455,
24,
1090
]
],
[
[
455,
24,
1032
],
[
1032,
63,
1090
]
],
[
[
455,
24,
901
],
[
901,
24,
1090
]
],
[
[
455,
63,
1290
],
[
1290,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
... |
DB00682 | DB06273 | 126 | 980 | [
"DDInter1951",
"DDInter1824"
] | Warfarin | Tocilizumab | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
126,
24,
980
]
],
[
[
126,
63,
1461
],
[
1461,
23,
980
]
],
[
[
126,
62,
494
],
[
494,
24,
980
]
],
[
[
126,
63,
597
],
[
597,
2... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Warfarin may cause a minor interaction that can limit clinical effects when taken with Disopyramide and Disopyramide ... |
DB00916 | DB05773 | 112 | 1,047 | [
"DDInter1202",
"DDInter1848"
] | Metronidazole | Trastuzumab emtansine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
112,
24,
1047
]
],
[
[
112,
64,
1091
],
[
1091,
24,
1047
]
],
[
[
112,
24,
375
],
[
375,
63,
1047
]
],
[
[
112,
24,
1112
],
[
1112,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Metronidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
... | Metronidazole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol ... |
DB00951 | DB06674 | 1,072 | 908 | [
"DDInter986",
"DDInter837"
] | Isoniazid | Golimumab | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
1072,
24,
908
]
],
[
[
1072,
63,
268
],
[
268,
24,
908
]
],
[
[
1072,
24,
1487
],
[
1487,
24,
908
]
],
[
[
1072,
24,
1434
],
[
1434,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Hy... |
DB00242 | DB10429 | 1,064 | 200 | [
"DDInter392",
"DDInter282"
] | Cladribine | Candida albicans | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1064,
24,
200
]
],
[
[
1064,
25,
1096
],
[
1096,
24,
200
]
],
[
[
1064,
64,
168
],
[
168,
24,
200
]
],
[
[
1064,
25,
1019
],
[
1019,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
],
[
... | Cladribine may lead to a major life threatening interaction when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Cladribine may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may c... |
DB11703 | DB11932 | 405 | 327 | [
"DDInter9",
"DDInter3"
] | Acalabrutinib | Abametapir (topical) | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
405,
24,
327
]
],
[
[
405,
25,
283
],
[
283,
63,
327
]
],
[
[
405,
64,
292
],
[
292,
24,
327
]
],
[
[
405,
63,
1101
],
[
1101,
2... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedr... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Acalabrutinib may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Acalabrutinib may l... |
DB01611 | DB05773 | 1,487 | 1,047 | [
"DDInter893",
"DDInter1848"
] | Hydroxychloroquine | Trastuzumab emtansine | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1487,
24,
1047
]
],
[
[
1487,
63,
1091
],
[
1091,
24,
1047
]
],
[
[
1487,
24,
375
],
[
375,
63,
1047
]
],
[
[
1487,
25,
381
],
[
381,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00060 | DB01098 | 912 | 14 | [
"DDInter947",
"DDInter1622"
] | Interferon beta-1a | Rosuvastatin | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
912,
24,
14
]
],
[
[
912,
24,
671
],
[
671,
24,
14
]
],
[
[
912,
24,
600
],
[
600,
23,
14
]
],
[
[
912,
63,
305
],
[
305,
24,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastat... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with F... |
DB00011 | DB08886 | 1,451 | 637 | [
"DDInter944",
"DDInter126"
] | Interferon alfa-n1 | Asparaginase Erwinia chrysanthemi | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
1451,
24,
637
]
],
[
[
1451,
63,
491
],
[
491,
24,
637
]
],
[
[
1451,
25,
72
],
[
72,
24,
637
]
],
[
[
1451,
24,
467
],
[
467,
2... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Interferon alfa-n1 may lead to a major life threatening int... |
DB00862 | DB09065 | 1,005 | 760 | [
"DDInter1918",
"DDInter424"
] | Vardenafil | Cobicistat | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1005,
25,
760
]
],
[
[
1005,
24,
1374
],
[
1374,
23,
760
]
],
[
[
1005,
63,
723
],
[
723,
24,
760
]
],
[
[
1005,
25,
868
],
[
868,
... | [
[
[
"Vardenafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiratero... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepi... |
DB00461 | DB00795 | 598 | 50 | [
"DDInter1254",
"DDInter1725"
] | Nabumetone | Sulfasalazine | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Moderate | 1 | [
[
[
598,
24,
50
]
],
[
[
598,
24,
712
],
[
712,
1,
50
]
],
[
[
598,
10,
11577
],
[
11577,
44,
50
]
],
[
[
598,
6,
10522
],
[
10522,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine (Compound) resembles Sulfasalazine (Compound)
Nabumetone (Compound) palliates rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Sulfasalazine (Compound)
Nabumetone (Compound... |
DB00366 | DB00747 | 1,594 | 1,442 | [
"DDInter600",
"DDInter1647"
] | Doxylamine | Scopolamine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
1594,
24,
1442
]
],
[
[
1594,
24,
19
],
[
19,
24,
1442
]
],
[
[
1594,
63,
1089
],
[
1089,
24,
1442
]
],
[
[
1594,
6,
7992
],
[
7992,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium and Ip... |
DB00934 | DB09272 | 413 | 412 | [
"DDInter1124",
"DDInter632"
] | Maprotiline | Eluxadoline | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
413,
24,
412
]
],
[
[
413,
63,
1594
],
[
1594,
24,
412
]
],
[
[
413,
24,
830
],
[
830,
24,
412
]
],
[
[
413,
24,
407
],
[
407,
6... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and P... |
DB00496 | DB00792 | 194 | 832 | [
"DDInter480",
"DDInter1878"
] | Darifenacin | Tripelennamine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
194,
24,
832
]
],
[
[
194,
24,
100
],
[
100,
63,
832
]
],
[
[
194,
63,
1594
],
[
1594,
24,
832
]
],
[
[
194,
25,
888
],
[
888,
1... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Doxyl... |
DB01143 | DB01162 | 923 | 195 | [
"DDInter65",
"DDInter1767"
] | Amifostine | Terazosin | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Moderate | 1 | [
[
[
923,
24,
195
]
],
[
[
923,
63,
1205
],
[
1205,
40,
195
]
],
[
[
923,
18,
2801
],
[
2801,
57,
195
]
],
[
[
923,
21,
28743
],
[
28743,
... | [
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terazosin"
]
],
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prazosin"
],
[
... | Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Prazosin and Prazosin (Compound) resembles Terazosin (Compound)
Amifostine (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Terazosin (Compound)
Amifostine (Compound) causes Atrial fibrillation (Side Eff... |
DB00023 | DB06273 | 305 | 980 | [
"DDInter127",
"DDInter1824"
] | Asparaginase Escherichia coli | Tocilizumab | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
305,
24,
980
]
],
[
[
305,
24,
1525
],
[
1525,
63,
980
]
],
[
[
305,
24,
139
],
[
139,
24,
980
]
],
[
[
305,
63,
491
],
[
491,
2... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Dienogest and Dienogest may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases ... |
DB00182 | DB01168 | 80 | 1,053 | [
"DDInter84",
"DDInter1526"
] | Amphetamine | Procarbazine | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 ... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
80,
25,
1053
]
],
[
[
80,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
80,
24,
480
],
[
480,
24,
1053
]
],
[
[
80,
24,
659
],
[
659,
... | [
[
[
"Amphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Amphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Co... | Amphetamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Proca... |
DB01576 | DB09104 | 93 | 286 | [
"DDInter526",
"DDInter1118"
] | Dextroamphetamine | Magnesium hydroxide | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
93,
24,
286
]
],
[
[
93,
63,
820
],
[
820,
23,
286
]
],
[
[
93,
1,
633
],
[
633,
24,
286
]
],
[
[
93,
63,
688
],
[
688,
24,
... | [
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alim... | Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Dextroamphetamine (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine may caus... |
DB00988 | DB06704 | 817 | 247 | [
"DDInter584",
"DDInter951"
] | Dopamine | Iobenguane (I-123) | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
817,
37,
247
]
],
[
[
817,
6,
7390
],
[
7390,
45,
247
]
],
[
[
817,
21,
28762
],
[
28762,
60,
247
]
],
[
[
817,
24,
820
],
[
820,
... | [
[
[
"Dopamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Dopamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
... | Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Dopamine may lead to a major life threatening interaction when taken with Iobenguane
Dopamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Dopamine (Compound) causes Headache (Si... |
DB00258 | DB08930 | 666 | 1,459 | [
"DDInter270",
"DDInter582"
] | Calcium acetate | Dolutegravir | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and ... | Major | 2 | [
[
[
666,
25,
1459
]
],
[
[
666,
21,
28722
],
[
28722,
60,
1459
]
],
[
[
666,
21,
28722
],
[
28722,
60,
353
],
[
353,
23,
1459
]
],
[
[
666... | [
[
[
"Calcium acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolutegravir"
]
],
[
[
"Calcium acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v}... | Calcium acetate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Dolutegravir (Compound)
Calcium acetate (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Griseofulvin (Compound) and Griseofulvin may cause a minor interaction that can limit clinical effects when ta... |
DB08860 | DB12941 | 788 | 466 | [
"DDInter1479",
"DDInter481"
] | Pitavastatin | Darolutamide | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
788,
24,
466
]
],
[
[
788,
24,
484
],
[
484,
23,
466
]
],
[
[
788,
63,
597
],
[
597,
23,
466
]
],
[
[
788,
24,
1040
],
[
1040,
2... | [
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol... |
DB00976 | DB06616 | 1,056 | 594 | [
"DDInter1758",
"DDInter224"
] | Telithromycin | Bosutinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
1056,
25,
594
]
],
[
[
1056,
63,
883
],
[
883,
1,
594
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
594
]
],
[
[
1056,
21,
29231
],
[
29231,
... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefiti... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Telithromycin (Compound) causes Cardiac disorder (Side Effect) a... |
DB00401 | DB00486 | 84 | 1,614 | [
"DDInter1298",
"DDInter1253"
] | Nisoldipine | Nabilone | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
84,
24,
1614
]
],
[
[
84,
24,
530
],
[
530,
1,
1614
]
],
[
[
84,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
84,
63,
999
],
[
999,
2... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Nisoldipine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Nisoldipine may cause ... |
DB00067 | DB00468 | 317 | 1,424 | [
"DDInter1921",
"DDInter1557"
] | Vasopressin | Quinine | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
317,
24,
1424
]
],
[
[
317,
23,
112
],
[
112,
62,
1424
]
],
[
[
317,
24,
480
],
[
480,
63,
1424
]
],
[
[
317,
24,
618
],
[
618,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formo... |
DB00277 | DB15762 | 1,031 | 725 | [
"DDInter1791",
"DDInter1644"
] | Theophylline | Satralizumab | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
1031,
24,
725
]
],
[
[
1031,
24,
1362
],
[
1362,
24,
725
]
],
[
[
1031,
63,
912
],
[
912,
24,
725
]
],
[
[
1031,
24,
1531
],
[
1531,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a ... |
DB11730 | DB13074 | 351 | 877 | [
"DDInter1588",
"DDInter1110"
] | Ribociclib | Macimorelin | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
351,
25,
877
]
],
[
[
351,
62,
112
],
[
112,
23,
877
]
],
[
[
351,
24,
1320
],
[
1320,
24,
877
]
],
[
[
351,
64,
651
],
[
651,
2... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Ribociclib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elago... |
DB00420 | DB05812 | 508 | 1,374 | [
"DDInter1532",
"DDInter8"
] | Promazine | Abiraterone | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
508,
24,
1374
]
],
[
[
508,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
508,
23,
112
],
[
112,
23,
1374
]
],
[
[
508,
63,
1494
],
[
1494,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Promazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Promazine may ca... |
DB01197 | DB14018 | 1,603 | 431 | [
"DDInter292",
"DDInter244"
] | Captopril | Bromotheophylline | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a ... | Moderate | 1 | [
[
[
1603,
24,
431
]
],
[
[
1603,
63,
1061
],
[
1061,
24,
431
]
],
[
[
1603,
24,
885
],
[
885,
24,
431
]
],
[
[
1603,
40,
610
],
[
610,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromotheophylline"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Bromotheophylline
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol... |
DB00582 | DB00758 | 1,622 | 1,347 | [
"DDInter1946",
"DDInter413"
] | Voriconazole | Clopidogrel | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
1622,
24,
1347
]
],
[
[
1622,
6,
7603
],
[
7603,
45,
1347
]
],
[
[
1622,
21,
28744
],
[
28744,
60,
1347
]
],
[
[
1622,
25,
1411
],
[
1... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compou... | Voriconazole (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Clopidogrel (Compound)
Voriconazole (Compound) causes Deafness (Side Effect) and Deafness (Side Effect) is caused by Clopidogrel (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide ... |
DB05239 | DB09054 | 866 | 384 | [
"DDInter425",
"DDInter905"
] | Cobimetinib | Idelalisib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
866,
25,
384
]
],
[
[
866,
24,
1627
],
[
1627,
62,
384
]
],
[
[
866,
25,
555
],
[
555,
23,
384
]
],
[
[
866,
64,
307
],
[
307,
2... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabi... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Cobimetinib may lead to a major life threatening interaction when taken with Netupitant and Netupitant may caus... |
DB00867 | DB08865 | 1,052 | 1,593 | [
"DDInter1606",
"DDInter448"
] | Ritodrine | Crizotinib | Adrenergic beta-agonist used to control premature labor. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1052,
25,
1593
]
],
[
[
1052,
7,
4507
],
[
4507,
46,
1593
]
],
[
[
1052,
18,
4884
],
[
4884,
57,
1593
]
],
[
[
1052,
24,
455
],
[
455,... | [
[
[
"Ritodrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Ritodrine",
"{u} (Compound) upregulates {v} (Gene)",
"BMP4"
],
[
"BMP4",
"{u} (Gene) is upregulated by {v} (Compound)",
"C... | Ritodrine (Compound) upregulates BMP4 (Gene) and BMP4 (Gene) is upregulated by Crizotinib (Compound)
Ritodrine (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Crizotinib (Compound)
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salme... |
DB00682 | DB00794 | 126 | 759 | [
"DDInter1951",
"DDInter1521"
] | Warfarin | Primidone | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Major | 2 | [
[
[
126,
25,
759
]
],
[
[
126,
25,
697
],
[
697,
40,
759
]
],
[
[
126,
63,
362
],
[
362,
1,
759
]
],
[
[
126,
24,
157
],
[
157,
1,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} ... | Warfarin may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound)
Warfarin may caus... |
DB00254 | DB00808 | 964 | 1,605 | [
"DDInter598",
"DDInter916"
] | Doxycycline | Indapamide | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Minor | 0 | [
[
[
964,
23,
1605
]
],
[
[
964,
23,
811
],
[
811,
1,
1605
]
],
[
[
964,
6,
8374
],
[
8374,
45,
1605
]
],
[
[
964,
1,
1669
],
[
1669,
... | [
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
... | Doxycycline may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Doxycycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indapamide (Compound)
Doxycycline (Compound) resembles Minocycline (Compound) and Minocy... |
DB00581 | DB00889 | 355 | 1,133 | [
"DDInter1018",
"DDInter840"
] | Lactulose | Granisetron | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
355,
24,
1133
]
],
[
[
355,
21,
29113
],
[
29113,
60,
1133
]
],
[
[
355,
24,
1213
],
[
1213,
63,
1133
]
],
[
[
355,
24,
1005
],
[
1005... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokalaemia"
],
[
"Hypokalaemia",
"{u} (Side Effect) is... | Lactulose (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Granisetron (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Gran... |
DB01088 | DB01197 | 714 | 1,603 | [
"DDInter908",
"DDInter292"
] | Iloprost | Captopril | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
714,
24,
1603
]
],
[
[
714,
63,
610
],
[
610,
1,
1603
]
],
[
[
714,
24,
1053
],
[
1053,
24,
1603
]
],
[
[
714,
24,
549
],
[
549,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
"E... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could ex... |
DB00554 | DB00586 | 1,027 | 1,512 | [
"DDInter1478",
"DDInter537"
] | Piroxicam | Diclofenac | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1027,
24,
1512
]
],
[
[
1027,
6,
3486
],
[
3486,
45,
1512
]
],
[
[
1027,
10,
11577
],
[
11577,
49,
1512
]
],
[
[
1027,
54,
19122
],
[
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Piroxicam (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Diclofenac (Compound)
Piroxicam (Compound) palliates rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Diclofenac (Compound)
Piroxicam (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic ... |
DB00982 | DB09054 | 1,517 | 384 | [
"DDInter991",
"DDInter905"
] | Isotretinoin | Idelalisib | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1517,
24,
384
]
],
[
[
1517,
24,
1627
],
[
1627,
62,
384
]
],
[
[
1517,
25,
464
],
[
464,
62,
384
]
],
[
[
1517,
63,
305
],
[
305,
... | [
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
... | Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Isotretinoin may lead to a major life threatening interaction when taken with Eravacycline and Eravacycline ma... |
DB00432 | DB08868 | 1,083 | 1,011 | [
"DDInter1868",
"DDInter737"
] | Trifluridine | Fingolimod | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1083,
25,
1011
]
],
[
[
1083,
21,
28817
],
[
28817,
60,
1011
]
],
[
[
1083,
24,
748
],
[
748,
63,
1011
]
],
[
[
1083,
24,
1136
],
[
11... | [
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Trifluridine",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effect) is cause... | Trifluridine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Fingolimod (Compound)
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases... |
DB00497 | DB12332 | 828 | 1,619 | [
"DDInter1366",
"DDInter1626"
] | Oxycodone | Rucaparib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
828,
24,
1619
]
],
[
[
828,
24,
222
],
[
222,
23,
1619
]
],
[
[
828,
24,
259
],
[
259,
24,
1619
]
],
[
[
828,
25,
1419
],
[
1419,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacep... |
DB00366 | DB00985 | 1,594 | 1,443 | [
"DDInter600",
"DDInter562"
] | Doxylamine | Dimenhydrinate | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
1594,
24,
1443
]
],
[
[
1594,
40,
11296
],
[
11296,
1,
1443
]
],
[
[
1594,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
1594,
63,
357
],
[
35... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Bromodiphenhydramine"
],
[
"Bromodiphenhydramine",
... | Doxylamine (Compound) resembles Bromodiphenhydramine (Compound) and Bromodiphenhydramine (Compound) resembles Dimenhydrinate (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate di... |
DB01159 | DB09098 | 419 | 98 | [
"DDInter854",
"DDInter1700"
] | Halothane | Somatrem | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
419,
24,
98
]
],
[
[
419,
24,
159
],
[
159,
63,
98
]
],
[
[
419,
64,
11
],
[
11,
24,
98
]
],
[
[
419,
24,
609
],
[
609,
24,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Halothane may lead to a major life threatening interaction when taken with Toremifene and Toremifene may caus... |
DB04575 | DB14568 | 35 | 982 | [
"DDInter1555",
"DDInter1000"
] | Quinestrol | Ivosidenib | The 3-cyclopentyl ether of ethinyl estradiol. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
35,
24,
982
]
],
[
[
35,
63,
1101
],
[
1101,
23,
982
]
],
[
[
35,
64,
770
],
[
770,
24,
982
]
],
[
[
35,
1,
1336
],
[
1336,
24,
... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Quinestrol may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause ... |
DB01210 | DB12267 | 668 | 1,476 | [
"DDInter1050",
"DDInter233"
] | Levobunolol (ophthalmic) | Brigatinib | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
668,
24,
1476
]
],
[
[
668,
40,
729
],
[
729,
24,
1476
]
],
[
[
668,
24,
1276
],
[
1276,
24,
1476
]
],
[
[
668,
1,
699
],
[
699,
... | [
[
[
"Levobunolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Levobunolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moder... | Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Levobunolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Levobunolol may cause a moderate interaction that could ... |
DB01220 | DB12141 | 1,088 | 971 | [
"DDInter1593",
"DDInter817"
] | Rifaximin | Gilteritinib | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduc... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1088,
24,
971
]
],
[
[
1088,
24,
466
],
[
466,
62,
971
]
],
[
[
1088,
24,
1097
],
[
1097,
24,
971
]
],
[
[
1088,
40,
690
],
[
690,
... | [
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasm... |
DB01168 | DB12161 | 1,053 | 730 | [
"DDInter1526",
"DDInter512"
] | Procarbazine | Deutetrabenazine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Major | 2 | [
[
[
1053,
25,
730
]
],
[
[
1053,
63,
100
],
[
100,
24,
730
]
],
[
[
1053,
64,
1264
],
[
1264,
24,
730
]
],
[
[
1053,
24,
830
],
[
830,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Procarbazine may lead to a major life threatening interaction when taken with Doxepin and Doxe... |
DB00397 | DB01394 | 1,466 | 1,554 | [
"DDInter1458",
"DDInter431"
] | Phenylpropanolamine | Colchicine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has ... | Minor | 0 | [
[
[
1466,
23,
1554
]
],
[
[
1466,
18,
2183
],
[
2183,
46,
1554
]
],
[
[
1466,
21,
28787
],
[
28787,
60,
1554
]
],
[
[
1466,
63,
1636
],
[
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Colchicine"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is upr... | Phenylpropanolamine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is upregulated by Colchicine (Compound)
Phenylpropanolamine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Colchicine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate dis... |
DB01159 | DB11718 | 419 | 927 | [
"DDInter854",
"DDInter640"
] | Halothane | Encorafenib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
419,
24,
927
]
],
[
[
419,
62,
112
],
[
112,
23,
927
]
],
[
[
419,
24,
659
],
[
659,
24,
927
]
],
[
[
419,
63,
1520
],
[
1520,
2... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilan... |
DB00333 | DB01234 | 576 | 1,220 | [
"DDInter1166",
"DDInter513"
] | Methadone | Dexamethasone | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
576,
25,
1220
]
],
[
[
576,
6,
21998
],
[
21998,
45,
1220
]
],
[
[
576,
21,
29317
],
[
29317,
60,
1220
]
],
[
[
576,
24,
688
],
[
688,... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (Compoun... | Methadone (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound)
Methadone (Compound) causes Multiple fractures (Side Effect) and Multiple fractures (Side Effect) is caused by Dexamethasone (Compound)
Methadone may cause a moderate interaction that could exacerbate disea... |
DB00978 | DB01042 | 739 | 1,307 | [
"DDInter1084",
"DDInter1144"
] | Lomefloxacin | Melphalan | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Minor | 0 | [
[
[
739,
23,
1307
]
],
[
[
739,
24,
848
],
[
848,
40,
1307
]
],
[
[
739,
21,
28766
],
[
28766,
60,
1307
]
],
[
[
739,
1,
956
],
[
956,
... | [
[
[
"Lomefloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Melphalan"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Melphalan (Compound)
Lomefloxacin (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Melphalan (Compound)
Lomefloxacin (Compound) resembles Norflo... |
DB00930 | DB01124 | 166 | 1,411 | [
"DDInter432",
"DDInter1828"
] | Colesevelam | Tolbutamide | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
166,
24,
1411
]
],
[
[
166,
24,
959
],
[
959,
40,
1411
]
],
[
[
166,
63,
245
],
[
245,
40,
1411
]
],
[
[
166,
63,
126
],
[
126,
... | [
[
[
"Colesevelam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Colesevelam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compou... |
DB00959 | DB01193 | 1,486 | 819 | [
"DDInter1191",
"DDInter12"
] | Methylprednisolone | Acebutolol | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
1486,
24,
819
]
],
[
[
1486,
24,
887
],
[
887,
1,
819
]
],
[
[
1486,
63,
1121
],
[
1121,
1,
819
]
],
[
[
1486,
6,
4973
],
[
4973,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol... |
DB00574 | DB01156 | 121 | 593 | [
"DDInter717",
"DDInter252"
] | Fenfluramine | Bupropion | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
121,
25,
593
]
],
[
[
121,
24,
256
],
[
256,
62,
593
]
],
[
[
121,
23,
211
],
[
211,
23,
593
]
],
[
[
121,
24,
126
],
[
126,
24,... | [
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
[
"Prasugre... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Bupropion
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine and Tolterod... |
DB00631 | DB00798 | 372 | 1,132 | [
"DDInter405",
"DDInter815"
] | Clofarabine | Gentamicin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Moderate | 1 | [
[
[
372,
24,
1132
]
],
[
[
372,
21,
28703
],
[
28703,
60,
1132
]
],
[
[
372,
24,
664
],
[
664,
23,
1132
]
],
[
[
372,
24,
361
],
[
361,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caus... | Clofarabine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gentamicin (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Gentami... |
DB00938 | DB01236 | 455 | 679 | [
"DDInter1635",
"DDInter1664"
] | Salmeterol | Sevoflurane | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
455,
24,
679
]
],
[
[
455,
63,
1262
],
[
1262,
40,
679
]
],
[
[
455,
6,
8374
],
[
8374,
45,
679
]
],
[
[
455,
21,
28862
],
[
28862,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Salmeterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Salmeterol (Compound) causes Ventricular tachycardia (Side Effec... |
DB00563 | DB06210 | 663 | 72 | [
"DDInter1174",
"DDInter631"
] | Methotrexate | Eltrombopag | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
663,
24,
72
]
],
[
[
663,
6,
15333
],
[
15333,
45,
72
]
],
[
[
663,
24,
384
],
[
384,
63,
72
]
],
[
[
663,
24,
467
],
[
467,
24,... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Comp... | Methotrexate (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Eltrombopag (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Methotrexa... |
DB08911 | DB12267 | 1,556 | 1,476 | [
"DDInter1842",
"DDInter233"
] | Trametinib | Brigatinib | Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1556,
24,
1476
]
],
[
[
1556,
24,
971
],
[
971,
24,
1476
]
],
[
[
1556,
63,
129
],
[
129,
25,
1476
]
],
[
[
1556,
24,
384
],
[
384,
... | [
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
... | Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and ... |
DB00446 | DB01150 | 597 | 315 | [
"DDInter351",
"DDInter327"
] | Chloramphenicol | Cefprozil | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others. | Moderate | 1 | [
[
[
597,
24,
315
]
],
[
[
597,
24,
1024
],
[
1024,
40,
315
]
],
[
[
597,
24,
207
],
[
207,
1,
315
]
],
[
[
597,
21,
29455
],
[
29455,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefprozil"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefpodoxime and Cefpodoxime (Compound) resembles Cefprozil (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefradine and Cefradine (Compound) resembles Cefprozil (Co... |
DB01309 | DB09129 | 1,254 | 625 | [
"DDInter933",
"DDInter373"
] | Insulin glulisine | Chromic chloride | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
1254,
24,
625
]
],
[
[
1254,
63,
127
],
[
127,
24,
625
]
],
[
[
1254,
24,
1385
],
[
1385,
63,
625
]
],
[
[
1254,
24,
52
],
[
52,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglito... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Semag... |
DB11793 | DB14443 | 738 | 987 | [
"DDInter1297",
"DDInter1931"
] | Niraparib | Vibrio cholerae CVD 103-HgR strain live antigen | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
738,
24,
987
]
],
[
[
738,
63,
1480
],
[
1480,
24,
987
]
],
[
[
738,
24,
1619
],
[
1619,
24,
987
]
],
[
[
738,
64,
581
],
[
581,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Niraparib may cause a moderate interaction that could exacerbate diseases when t... |
DB00722 | DB06715 | 743 | 239 | [
"DDInter1079",
"DDInter1500"
] | Lisinopril | Potassium Iodide | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Major | 2 | [
[
[
743,
25,
239
]
],
[
[
743,
21,
29196
],
[
29196,
60,
239
]
],
[
[
743,
63,
1274
],
[
1274,
24,
239
]
],
[
[
743,
24,
848
],
[
848,
... | [
[
[
"Lisinopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Lisinopril",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused ... | Lisinopril (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Potassium Iodide (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when ta... |
DB00710 | DB00738 | 1,199 | 485 | [
"DDInter897",
"DDInter1420"
] | Ibandronate | Pentamidine | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1199,
24,
485
]
],
[
[
1199,
21,
29002
],
[
29002,
60,
485
]
],
[
[
1199,
24,
1272
],
[
1272,
63,
485
]
],
[
[
1199,
63,
1555
],
[
155... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Ibandronate",
"{u} (Compound) causes {v} (Side Effect)",
"Azotaemia"
],
[
"Azotaemia",
"{u} (Side Effect) is c... | Ibandronate (Compound) causes Azotaemia (Side Effect) and Azotaemia (Side Effect) is caused by Pentamidine (Compound)
Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Pe... |
DB01324 | DB11348 | 178 | 1,065 | [
"DDInter1490",
"DDInter279"
] | Polythiazide | Calcium Phosphate | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
178,
24,
1065
]
],
[
[
178,
1,
1014
],
[
1014,
24,
1065
]
],
[
[
178,
62,
1620
],
[
1620,
24,
1065
]
],
[
[
178,
1,
1014
],
[
1014,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
"{u} may ... | Polythiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Polythiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate inter... |
DB01438 | DB09122 | 585 | 1,613 | [
"DDInter1438",
"DDInter1409"
] | Phenazopyridine | Peginterferon beta-1a | Phenazopyridine, also known as Pyridium, is a urinary tract analgesic used for the short-term management of urinary tract irritation and its associated unpleasant symptoms such as burning and pain during urination. In the USA, this drug was previously marked by Roche but has been discontinued by the FDA. It is still us... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
585,
24,
1613
]
],
[
[
585,
63,
267
],
[
267,
24,
1613
]
],
[
[
585,
24,
850
],
[
850,
24,
1613
]
],
[
[
585,
64,
1377
],
[
1377,
... | [
[
[
"Phenazopyridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Phenazopyridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltre... | Phenazopyridine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Phenazopyridine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00013 | DB00586 | 1,255 | 1,512 | [
"DDInter1905",
"DDInter537"
] | Urokinase | Diclofenac | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1255,
24,
1512
]
],
[
[
1255,
23,
297
],
[
297,
62,
1512
]
],
[
[
1255,
24,
885
],
[
885,
63,
1512
]
],
[
[
1255,
24,
598
],
[
598,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Diclofenac
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cau... |
DB01159 | DB06663 | 419 | 1,154 | [
"DDInter854",
"DDInter1398"
] | Halothane | Pasireotide | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
419,
25,
1154
]
],
[
[
419,
62,
112
],
[
112,
23,
1154
]
],
[
[
419,
24,
1662
],
[
1662,
63,
1154
]
],
[
[
419,
63,
480
],
[
480,
... | [
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid an... |
DB00747 | DB01176 | 1,442 | 537 | [
"DDInter1647",
"DDInter453"
] | Scopolamine | Cyclizine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1442,
24,
537
]
],
[
[
1442,
24,
1511
],
[
1511,
63,
537
]
],
[
[
1442,
24,
104
],
[
104,
1,
537
]
],
[
[
1442,
63,
13
],
[
13,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and M... |
DB09065 | DB12825 | 760 | 1,375 | [
"DDInter424",
"DDInter1032"
] | Cobicistat | Lefamulin | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
760,
25,
1375
]
],
[
[
760,
25,
159
],
[
159,
63,
1375
]
],
[
[
760,
63,
309
],
[
309,
24,
1375
]
],
[
[
760,
64,
976
],
[
976,
... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"... | Cobicistat may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may... |
DB01076 | DB09570 | 700 | 1,480 | [
"DDInter133",
"DDInter1002"
] | Atorvastatin | Ixazomib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
700,
24,
1480
]
],
[
[
700,
63,
268
],
[
268,
24,
1480
]
],
[
[
700,
24,
148
],
[
148,
63,
1480
]
],
[
[
700,
24,
98
],
[
98,
24... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01050 | DB12887 | 848 | 1,598 | [
"DDInter900",
"DDInter1750"
] | Ibuprofen | Tazemetostat | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
848,
24,
1598
]
],
[
[
848,
24,
738
],
[
738,
24,
1598
]
],
[
[
848,
62,
752
],
[
752,
24,
1598
]
],
[
[
848,
63,
891
],
[
891,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine... |
DB00843 | DB08895 | 479 | 976 | [
"DDInter583",
"DDInter1825"
] | Donepezil | Tofacitinib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
479,
24,
976
]
],
[
[
479,
24,
214
],
[
214,
63,
976
]
],
[
[
479,
23,
86
],
[
86,
24,
976
]
],
[
[
479,
62,
723
],
[
723,
24,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Miconazole and Micon... |
DB00586 | DB00749 | 1,512 | 59 | [
"DDInter537",
"DDInter699"
] | Diclofenac | Etodolac | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
1512,
24,
59
]
],
[
[
1512,
6,
6017
],
[
6017,
45,
59
]
],
[
[
1512,
10,
11666
],
[
11666,
49,
59
]
],
[
[
1512,
54,
19122
],
[
19122,... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Diclofenac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Etodolac (Compound)
Diclofenac (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Etodolac (Compound)
Diclofenac (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and No... |
DB00196 | DB01611 | 600 | 1,487 | [
"DDInter743",
"DDInter893"
] | Fluconazole | Hydroxychloroquine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
600,
25,
1487
]
],
[
[
600,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
600,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
600,
23,
1247
],
[
1247... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Fluconazole (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compo... |
DB00582 | DB12141 | 1,622 | 971 | [
"DDInter1946",
"DDInter817"
] | Voriconazole | Gilteritinib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
1622,
25,
971
]
],
[
[
1622,
25,
1135
],
[
1135,
23,
971
]
],
[
[
1622,
23,
466
],
[
466,
62,
971
]
],
[
[
1622,
23,
112
],
[
112,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{... | Voriconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may ca... |
DB00284 | DB09122 | 1,647 | 1,613 | [
"DDInter11",
"DDInter1409"
] | Acarbose | Peginterferon beta-1a | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1647,
24,
1613
]
],
[
[
1647,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1647,
63,
168
],
[
168,
24,
1613
]
],
[
[
1647,
24,
1518
],
[
1518... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib a... |
DB00731 | DB01241 | 1,144 | 1,206 | [
"DDInter1269",
"DDInter812"
] | Nateglinide | Gemfibrozil | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA appr... | Moderate | 1 | [
[
[
1144,
24,
1206
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
1206
]
],
[
[
1144,
21,
29232
],
[
29232,
60,
1206
]
],
[
[
1144,
24,
1476
],
[
1... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound)
Nateglinide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Gemfibrozil (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and... |
DB06616 | DB11915 | 594 | 1,293 | [
"DDInter224",
"DDInter1909"
] | Bosutinib | Valbenazine | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
594,
24,
1293
]
],
[
[
594,
62,
112
],
[
112,
23,
1293
]
],
[
[
594,
63,
521
],
[
521,
24,
1293
]
],
[
[
594,
25,
283
],
[
283,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Bosutinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Valbenazine
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Gosere... |
DB08816 | DB14006 | 578 | 972 | [
"DDInter1802",
"DDInter370"
] | Ticagrelor | Choline salicylate | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
578,
24,
972
]
],
[
[
578,
64,
553
],
[
553,
24,
972
]
],
[
[
578,
63,
291
],
[
291,
24,
972
]
],
[
[
578,
25,
498
],
[
498,
24,... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"... | Ticagrelor may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroba... |
DB00533 | DB12364 | 1,416 | 1,421 | [
"DDInter1613",
"DDInter200"
] | Rofecoxib | Betrixaban | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1416,
24,
1421
]
],
[
[
1416,
63,
305
],
[
305,
24,
1421
]
],
[
[
1416,
24,
298
],
[
298,
24,
1421
]
],
[
[
1416,
24,
714
],
[
714,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases w... |
DB00582 | DB00889 | 1,622 | 1,133 | [
"DDInter1946",
"DDInter840"
] | Voriconazole | Granisetron | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
1622,
24,
1133
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
1622,
21,
28851
],
[
28851,
60,
1133
]
],
[
[
1622,
23,
112
],
[
11... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Voriconazole (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Granisetron (Compound)
Voriconazole may cause a minor interaction that can limit clinical effects... |
DB00544 | DB01059 | 970 | 956 | [
"DDInter757",
"DDInter1313"
] | Fluorouracil | Norfloxacin | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
970,
23,
956
]
],
[
[
970,
23,
872
],
[
872,
40,
956
]
],
[
[
970,
62,
1176
],
[
1176,
1,
956
]
],
[
[
970,
23,
1539
],
[
1539,
... | [
[
[
"Fluorouracil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Fluorouracil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[... | Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Fluorouracil may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (... |
DB00224 | DB08907 | 215 | 1,344 | [
"DDInter917",
"DDInter280"
] | Indinavir | Canagliflozin | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
215,
24,
1344
]
],
[
[
215,
24,
549
],
[
549,
1,
1344
]
],
[
[
215,
6,
5912
],
[
5912,
45,
1344
]
],
[
[
215,
21,
28873
],
[
28873,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Indinavir (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound)
Indinavir (Compound) causes Pancreatitis (Side Effect) and... |
DB01191 | DB06335 | 1,039 | 761 | [
"DDInter518",
"DDInter1646"
] | Dexfenfluramine | Saxagliptin | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1039,
24,
761
]
],
[
[
1039,
24,
1296
],
[
1296,
63,
761
]
],
[
[
1039,
64,
939
],
[
939,
24,
761
]
],
[
[
1039,
24,
478
],
[
478,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Dexfenfluramine may lead to a major life threatening interaction when taken with Benzphetamine... |
DB00673 | DB06228 | 723 | 792 | [
"DDInter112",
"DDInter1609"
] | Aprepitant | Rivaroxaban | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
723,
24,
792
]
],
[
[
723,
6,
7524
],
[
7524,
45,
792
]
],
[
[
723,
21,
28703
],
[
28703,
60,
792
]
],
[
[
723,
23,
307
],
[
307,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Aprepitant (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Rivaroxaban (Compound)
Aprepitant (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafin... |
DB01149 | DB06589 | 851 | 1,250 | [
"DDInter1274",
"DDInter1400"
] | Nefazodone | Pazopanib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
851,
25,
1250
]
],
[
[
851,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
851,
18,
4374
],
[
4374,
46,
1250
]
],
[
[
851,
7,
4759
],
[
4759,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"... | Nefazodone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Nefazodone (Compound) downregulates SDHB (Gene) and SDHB (Gene) is upregulated by Pazopanib (Compound)
Nefazodone (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Pazopanib (Compound)
Nefazodone (Compo... |
DB00402 | DB00662 | 1,407 | 717 | [
"DDInter685",
"DDInter1873"
] | Eszopiclone | Trimethobenzamide | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1407,
24,
717
]
],
[
[
1407,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1407,
63,
1594
],
[
1594,
24,
717
]
],
[
[
1407,
24,
13
],
[
13,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Eszopiclone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) ... | Eszopiclone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00851 | DB08827 | 611 | 990 | [
"DDInter463",
"DDInter1085"
] | Dacarbazine | Lomitapide | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
611,
25,
990
]
],
[
[
611,
24,
1362
],
[
1362,
63,
990
]
],
[
[
611,
24,
77
],
[
77,
24,
990
]
],
[
[
611,
63,
322
],
[
322,
24,... | [
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubic... |
DB00619 | DB11988 | 1,419 | 270 | [
"DDInter909",
"DDInter1321"
] | Imatinib | Ocrelizumab | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1419,
24,
270
]
],
[
[
1419,
24,
1060
],
[
1060,
63,
270
]
],
[
[
1419,
63,
134
],
[
134,
24,
270
]
],
[
[
1419,
25,
1019
],
[
1019,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelb... |
DB00850 | DB01278 | 1,630 | 1,021 | [
"DDInter1432",
"DDInter1506"
] | Perphenazine | Pramlintide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1630,
24,
1021
]
],
[
[
1630,
63,
1507
],
[
1507,
24,
1021
]
],
[
[
1630,
1,
9
],
[
9,
63,
1021
]
],
[
[
1630,
24,
22
],
[
22,
6... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Perphenazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate i... |
DB00734 | DB08868 | 1,664 | 1,011 | [
"DDInter1605",
"DDInter737"
] | Risperidone | Fingolimod | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1664,
25,
1011
]
],
[
[
1664,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1664,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
1664,
23,
112
],
[
... | [
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingo... | Risperidone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Risperidone (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronid... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.